3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Renal Cell
27
Neoplasms
9
Kidney Neoplasms
9
Carcinoma, Non-Small-Cell Lung
8
Carcinoma
7
Lung Neoplasms
4
Carcinoma, Hepatocellular
4
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Melanoma
2
Kidney Diseases
2
Advanced Solid Tumors
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Interventions
Rituximab
30
ibrutinib
26
Bendamustine Hydrochloride
18
Cyclophosphamide
17
acalabrutinib
14
fludarabine
13
Lenalidomide
11
zanubrutinib
10
venetoclax
9
Vincristine
7
Bortezomib
7
pirtobrutinib
5
brexucabtagene autoleucel
5
Prednisone
5
Doxorubicin
5
temsirolimus
4
parsaclisib
4
aflibercept
4
Gemcitabine
4
ublituximab
3
orelabrutinib
3
loncastuximab tesirine
3
idelalisib
3
ibritumomab tiuxetan
3
Sensitivity and Specificity
3
Antigens, CD19
3
tositumomab I-131
2
tazemetostat
2
pembrolizumab
2
fludarabine phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Mantle-Cell
×
Axitinib
×
Clear all
NCT00700258
2024-09-23
STAR-TOR
Pfizer
Completed
1,520 enrolled
24 charts